News
FDA panel unimpressed with data for Alzheimer’s drug aducanu...
The FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors have little doubt that the evidence for the drug is lacking.<
